Share on StockTwits

AstraZeneca plc (LON:AZN) was upgraded by equities researchers at Societe Generale to a “hold” rating in a research report issued on Monday, AnalystRatings.NET reports. The firm currently has a GBX 4,661 ($78.31) price target on the stock. Societe Generale’s target price suggests a potential upside of 14.24% from the stock’s previous close.

A number of other analysts have also recently weighed in on AZN. Analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc in a research note on Friday. Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Wednesday, April 23rd. They now have a GBX 3,830 ($64.35) price target on the stock. Finally, analysts at UBS AG reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, April 23rd. They now have a GBX 4,600 ($77.28) price target on the stock. Eight equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 3,795.54 ($63.77).

AstraZeneca plc (LON:AZN) opened at 4700.00 on Monday. AstraZeneca plc has a 52-week low of GBX 3028.50 and a 52-week high of GBX 4296.50. The stock’s 50-day moving average is GBX 3911. and its 200-day moving average is GBX 3670.. The company’s market cap is £59.267 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.